# Nura Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nura-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.nurabio.com
- Total disclosed funding: $215M
- Latest round: Series B (Jun 22, 2026)
- Investors on record: 4

## About

Nura Bio Inc., based in the US, focuses on developing innovative neuroprotective medicines targeting neurological diseases, specifically through advanced scientific research and therapeutic alternatives for conditions like Alzheimer’s disease and ALS.Founded in 2018 and headquartered in San Francisco, US, Nura Bio Inc. specializes in neuroprotective medications. The company has successfully raised USD 63 mn in Series A funding as part of a larger USD 141 mn round, with The Column Group leading the investment and Sanofi Ventures joining as a new investor. Nura Bio has completed a total of 3 deals, with the most recent deal dated September 17, 2024. The company is led by CEO Alpna Seth.Nura Bio™ develops neuroprotective medicines designed to treat various neurological diseases by targeting critical biological pathways related to axon degeneration and neuroimmune regulation. Their product offerings are rooted in extensive scientific research, promising advancements in treating disorders such as Alzheimer’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). These solutions are primarily marketed in North America and Europe, addressing the urgent demand for effective neurological disease treatments.Nura Bio generates revenue through the commercialization of its proprietary neuroprotective medicines, developed via rigorous scientific methodologies and clinical trials. Revenue streams include partnerships with healthcare providers and pharmaceutical companies, as well as potential licensing agreements for flagship products. The company employs a partnership model focusing on both direct-to-consumer sales and B2B collaborations, tailoring pricing plans to meet the needs of patients, healthcare systems, and research organizations. In June 2026, Nura Bio Inc. raised USD 73.8 million in series B funding led by The Column Group, with participation from Euclidean Capital, Samsara BioCapital, and Sanofi Ventures. The company will use the funding to advance clinical studies and develop treatments for neurological diseases targeting nerve cell.

## Funding rounds

- Series B, Jun 22, 2026, $74M — The Column Group, Sanofi Ventures, Euclidean Capital, Samsara BioCapital
- Series A, Sep 17, 2024, $68M — The Column Group, Sanofi Ventures, Euclidean Capital, Samsara BioCapital
- Series A, Jul 29, 2020, $73M — The Column Group, Euclidean Capital, Samsara BioCapital

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B
- Euclidean Capital — Series A, Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A, Series B